Tizanidine
Product Images NDC 10544-587

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 10544-587). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 2mg 90ct (Label Tizanidine Tabs 2mg Bpi(10544 587 90) Apotex(60505 0251 2) Rev2)

Tizanidine Tablets, USP 2mg, bottle label for 90 tablets by Blenheim Pharmacal, Inc. The label includes storage instructions, a warning about interchangeability with another product, dosage note to see package insert, and identifying information including NDC 10544-587-90 and manufacturer code 60505-0251-2. Bar code and expiration date placeholder are also visible.*

FDA Label Image

Structure (Tizanidine Imtb 01)

Chemical structure of the active ingredient tizanidine hydrochloride, showing the molecular arrangement including a chlorine-substituted aromatic ring and an imidazoline group.*

FDA Label Image

Graph (Tizanidine Imtb 02)

A line graph titled "Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions." It shows plasma tizanidine concentration (ng/mL) on the vertical axis versus time in hours after dosing on the horizontal axis, with multiple lines comparing different formulations and conditions.*

FDA Label Image

Graph (Tizanidine Imtb 03)

A line graph depicting the mean change in muscle tone from baseline over 6 hours post-dose in a single-dose study. The y-axis shows improvement in Ashworth Score with negative values indicating improvement. Three lines compare 16 mg tizanidine, 8 mg tizanidine, and placebo, with 16 mg showing the greatest improvement, followed by 8 mg and placebo showing minimal change. Error bars represent 95% confidence intervals.*

FDA Label Image

Graph (Tizanidine Imtb 04)

A line graph titled 'Seven Week Study—Mean Change in Muscle Tone 0.5 to 2.5 Hours After Dosing as Measured by the Ashworth Scale ± 95% Confidence Interval,' showing the improvement in muscle tone from baseline. It compares tizanidine (mean dose 28.8 mg) and placebo at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint. Tizanidine shows negative Ashworth scores indicating improved muscle tone, with error bars depicting 95% confidence intervals, while placebo scores are near zero.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.